The AMPD3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population engineered to disrupt the AMPD3 gene in the human A-549 lung adenocarcinoma epithelial cell line. This pooled population of edited cells provides a genetically heterogeneous loss-of-function model for studying AMPD3-dependent pathways without clonal isolation, enabling robust assessment of gene function across a polyclonal background.
The parental A-549 cell line, originally established from the lung adenocarcinoma of a 58-year-old Caucasian male, exhibits adherent epithelial morphology and serves as a widely utilized in vitro model for human lung adenocarcinoma. Its relevance extends to cancer biology, respiratory research, and drug discovery studies, making it an ideal host for interrogating nucleotide metabolism and energy homeostasis.
AMPD3 encodes an adenosine monophosphate deaminase that catalyzes the hydrolytic deamination of AMP to IMP, a critical step in the purine nucleotide cycle and regulation of the adenylate pool. In these knockout cells, disruption of AMPD3 leads to accumulation of AMP and depletion of IMP, thereby altering the cellular AMP/ATP ratio and impairing AMPK-mediated energy sensing. AMPD3 is regulated by upstream factors including the AMP/ATP ratio, AMPK, mTORC1, protein kinase C, and AKT-mediated phosphorylation, while its activity influences downstream targets such as IMP, adenylate pool size, adenosine receptor signaling, sirtuins, and mTOR activity. It interacts with AMPD family members (AMPD1, AMPD2), ATP synthase (ATP5A1), myosin heavy chain, and AMPK subunits, and is allosterically controlled by ATP and GTP. Representative pathway components include adenylosuccinate synthetase (ADSS), adenylosuccinate lyase (ADSL), AMPK, mTOR, and adenosine receptors.
Within the A-549 lung adenocarcinoma context, loss of AMPD3 function disrupts nucleotide metabolism and energy homeostasis, potentially impacting cell proliferation and metabolic adaptation. This model is particularly relevant for investigating cancer metabolic reprogramming, as it allows dissection of the purine nucleotide cycle’s role in maintaining energy charge and anabolic precursor supply. The knockout system also facilitates studies of cross?talk between AMPK signaling and the mTOR pathway, both of which are frequently dysregulated in lung adenocarcinomas, and provides a platform for exploring the relationship between AMPD3 deficiency and hereditary myopathy with exercise intolerance or metabolic syndrome.
Researchers can employ this polyclonal knockout cell population in a variety of applications, including cancer metabolism studies, nucleotide metabolism analysis in lung adenocarcinoma, and drug response assays to agents such as 5?fluorouracil (5?FU) or AICAR. Detailed functional validation is achievable via AMPD enzyme activity assays, LC?MS?based metabolic profiling of nucleotides, and ATP/AMP ratio measurements. Further phenotypic characterization may involve cell proliferation (MTT) assays, Seahorse metabolic flux analysis, western blotting for AMPK and mTOR signaling components, migration/invasion assays, and drug sensitivity screening. By leveraging these assays, investigators can elucidate the contribution of AMPD3 to energy stress responses and metabolic adaptations in cancer cells. For further technical information, validation data, and ordering procedures, please contact Ascent Research.
